Kohno Takashi, Anzai Toshihisa, Naito Kotaro, Miyasho Taku, Okamoto Minoru, Yokota Hiroshi, Yamada Shingo, Maekawa Yuichiro, Takahashi Toshiyuki, Yoshikawa Tsutomu, Ishizaka Akitoshi, Ogawa Satoshi
Cardiopulmonary Division, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Cardiovasc Res. 2009 Feb 15;81(3):565-73. doi: 10.1093/cvr/cvn291. Epub 2008 Nov 3.
High-mobility group box 1 protein (HMGB1) is one of the recently defined damage-associated molecular pattern molecules derived from necrotic cells and activated macrophages. We investigated clinical implications of serum HMGB1 elevation in patients with acute myocardial infarction (MI). Then, we evaluated the effect of HMGB1 blockade on post-MI left ventricular (LV) remodelling in a rat MI model.
Serum HMGB1 levels were examined in patients with ST-elevation MI (n = 35). A higher peak serum HMGB1 level was associated with pump failure, cardiac rupture, and in-hospital cardiac death. Then, an experimental MI model was induced in male Wistar rats. The mRNA and protein expression of HMGB1 were increased in the infarcted area compared with those values observed in sham-operated rats. We administered neutralizing anti-HMGB1 antibody (MI/anti-H) or control antibody (MI/C) to MI rats subcutaneously for 7 days. The mRNA levels of tumour necrosis factor-alpha and interleukin-1beta and the number of macrophages in the infarcted area were reduced on day 3 in MI/anti-H rats compared with MI/C rats. Interestingly, HMGB1 blockade resulted in thinning and expansion of the infarct scar and marked hypertrophy of the non-infarcted area on day 14.
Elevated serum HMGB1 levels were associated with adverse clinical outcomes in patients with MI. However, HMGB1 blockade in a rat MI model aggravated LV remodelling, possibly through impairment of the infarct-healing process. HMGB1, a novel predictor of adverse clinical outcomes after MI, may have an essential role in the appropriate healing process after MI.
高迁移率族蛋白B1(HMGB1)是最近定义的一种源自坏死细胞和活化巨噬细胞的损伤相关分子模式分子。我们研究了急性心肌梗死(MI)患者血清HMGB1升高的临床意义。然后,我们在大鼠MI模型中评估了HMGB1阻断对MI后左心室(LV)重构的影响。
检测了ST段抬高型MI患者(n = 35)的血清HMGB1水平。血清HMGB1峰值水平较高与泵衰竭、心脏破裂和院内心源性死亡相关。然后,在雄性Wistar大鼠中诱导建立实验性MI模型。与假手术大鼠相比,梗死区域中HMGB1的mRNA和蛋白表达增加。我们对MI大鼠皮下注射中和抗HMGB1抗体(MI/抗-H)或对照抗体(MI/C),持续7天。与MI/C大鼠相比,MI/抗-H大鼠在第3天时梗死区域中肿瘤坏死因子-α和白细胞介素-1β的mRNA水平以及巨噬细胞数量减少。有趣的是,在第14天时,HMGB1阻断导致梗死瘢痕变薄和扩大以及非梗死区域明显肥大。
MI患者血清HMGB1水平升高与不良临床结局相关。然而,在大鼠MI模型中,HMGB1阻断加重了LV重构,可能是通过损害梗死愈合过程。HMGB1作为MI后不良临床结局的一种新的预测指标,可能在MI后的适当愈合过程中起重要作用。